Yarrow Bioscience (YARW) Enterprise Value (2016 - 2026)
Yarrow Bioscience's (YARW) quarterly Enterprise Value came in at -$24.9 million in Q1 2026, up 50.41% YoY from -$16.6 million in Q1 2025, and up 14.07% on a QoQ basis from -$29.0 million in Q4 2025.
Yarrow Bioscience (YARW) Enterprise Value (2016 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 11 years of Enterprise Value data on file, last reported at -$24.9 million in Q1 2026.
- Quarterly Enterprise Value rose 50.41% year-over-year to -$24.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.9 million (up 50.41% YoY) and the FY2025 annual result came in at -$29.0 million, up 52.84% from the prior year.
- Enterprise Value rose to -$24.9 million in Q1 2026, from -$29.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of $144000.0 in Q4 2022 to a low of -$86.0 million in Q1 2024.
- A 5-year average of -$40.7 million and a median of -$41.2 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value soared 123.8% — and 2024, when it slumped 129872.22%.
- Tracing YARW's Enterprise Value over 5 years: stood at $144000.0 in 2022, then tumbled by 43632.64% to -$62.7 million in 2023, then rose by 1.87% to -$61.5 million in 2024, then surged by 52.84% to -$29.0 million in 2025, then increased by 14.07% to -$24.9 million in 2026.
- The last three Enterprise Value figures came in at -$24.9 million (Q1 2026), -$29.0 million (Q4 2025), and -$39.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Yarrow Bioscience | 31.25 Mn | 8.33 Mn | - | -22.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.93 Mn |
| Mar 31, 2026 | -24.93 Mn |
| Dec 31, 2025 | -29.01 Mn |
| Jun 30, 2025 | -39.65 Mn |
| Mar 31, 2025 | -50.27 Mn |
| Dec 31, 2024 | -61.52 Mn |
| Sep 30, 2024 | -70.19 Mn |
| Jun 30, 2024 | -78.10 Mn |
| Mar 31, 2024 | -85.95 Mn |
| Dec 31, 2023 | -62.69 Mn |
| Sep 30, 2023 | -54,000.00 |
| Jun 30, 2023 | -20.63 Mn |
| Mar 31, 2023 | -67,000.00 |
| Dec 31, 2022 | 144,000.00 |
| Sep 30, 2022 | -35.51 Mn |
| Jun 30, 2022 | -42.81 Mn |
| Mar 31, 2022 | -50.50 Mn |
| Dec 31, 2021 | -605,000.00 |
| Sep 30, 2021 | -52.31 Mn |
| Jun 30, 2021 | -605,000.00 |